<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="research-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS One</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-title-group><journal-title>PLOS One</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, CA USA</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40408504</article-id><article-id pub-id-type="pmc">PMC12101740</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0324510</article-id><article-id pub-id-type="publisher-id">PONE-D-24-60389</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pharmacology</subject><subj-group><subject>Drugs</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject><subj-group><subject>Vancomycin</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Biology and Life Sciences</subject><subj-group><subject>Microbiology</subject><subj-group><subject>Microbial Control</subject><subj-group><subject>Antimicrobials</subject><subj-group><subject>Antibiotics</subject><subj-group><subject>Vancomycin</subject></subj-group></subj-group></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Nephrology</subject><subj-group><subject>Renal Diseases</subject><subj-group><subject>Chronic Kidney Disease</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Clinical Medicine</subject><subj-group><subject>Signs and Symptoms</subject><subj-group><subject>Sepsis</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Epidemiology</subject><subj-group><subject>Medical Risk Factors</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Physical Sciences</subject><subj-group><subject>Chemistry</subject><subj-group><subject>Chemical Elements</subject><subj-group><subject>Oxygen</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Respiratory Disorders</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Pulmonology</subject><subj-group><subject>Respiratory Disorders</subject><subj-group><subject>Respiratory Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Medical Conditions</subject><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Soft Tissue Infections</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v3"><subject>Medicine and Health Sciences</subject><subj-group><subject>Hematology</subject><subj-group><subject>Bloodstream Infections</subject></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Identification of risk factors for supra-therapeutic vancomycin trough levels in ventilator-assisted critical care patients based on integrated modeling and multi-criteria decision analysis</article-title><alt-title alt-title-type="running-head">Analysis of influencing factors in critically ill patients based on analytic hierarchy process</alt-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>Cao</surname><given-names>Xi</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/writing-original-draft/">Writing &#x02013; original draft</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Zhu</surname><given-names>Bi-ting</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="aff002" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Xie</surname><given-names>Cai-peng</given-names></name><role content-type="http://credit.niso.org/contributor-roles/software/">Software</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><role content-type="http://credit.niso.org/contributor-roles/writing-review-editing/">Writing &#x02013; review &#x00026; editing</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Cai</surname><given-names>Jing-yue</given-names></name><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Dong</surname><given-names>Ding-guo</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Chen</surname><given-names>Miao-ting</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/formal-analysis/">Formal analysis</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Huang</surname><given-names>Cheng-zhao</given-names></name><role content-type="http://credit.niso.org/contributor-roles/visualization/">Visualization</role><xref rid="aff003" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0003-3193-8950</contrib-id><name><surname>Lin</surname><given-names>Yong-chun</given-names></name><role content-type="http://credit.niso.org/contributor-roles/data-curation/">Data curation</role><role content-type="http://credit.niso.org/contributor-roles/investigation/">Investigation</role><role content-type="http://credit.niso.org/contributor-roles/methodology/">Methodology</role><role content-type="http://credit.niso.org/contributor-roles/validation/">Validation</role><xref rid="aff001" ref-type="aff">
<sup>1</sup>
</xref><xref rid="cor001" ref-type="corresp">*</xref></contrib></contrib-group><aff id="aff001"><label>1</label>
<addr-line>Department of Pharmacy, Central People&#x02019;s Hospital of Zhanjiang, Zhanjiang, China</addr-line></aff><aff id="aff002"><label>2</label>
<addr-line>Department of Pharmacy, Zhanjiang Potou District People&#x02018;s Hospital, Zhanjiang, China</addr-line></aff><aff id="aff003"><label>3</label>
<addr-line>Comprehensive Second Ward of Critical Care Medicine, Central People&#x02019;s Hospital of Zhanjiang, Zhanjiang, China</addr-line></aff><contrib-group><contrib contrib-type="editor"><name><surname>Liu</surname><given-names>Benjamin M.</given-names></name><role>Editor</role><xref rid="edit1" ref-type="aff"/></contrib></contrib-group><aff id="edit1">
<addr-line>Children's National Hospital, George Washington University, UNITED STATES OF AMERICA</addr-line>
</aff><author-notes><fn fn-type="COI-statement" id="coi001"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><corresp id="cor001">* E-mail: <email>cphofzj236_cx@163.com</email></corresp></author-notes><pub-date pub-type="epub"><day>23</day><month>5</month><year>2025</year></pub-date><pub-date pub-type="collection"><year>2025</year></pub-date><volume>20</volume><issue>5</issue><elocation-id>e0324510</elocation-id><history><date date-type="received"><day>12</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>25</day><month>4</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 Cao et al</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>Cao et al</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="pone.0324510.pdf">
</self-uri><abstract><p>To explore the risk factors influencing vancomycin trough concentration (<inline-formula id="pone.0324510.e001"><alternatives><graphic xlink:href="pone.0324510.e001.jpg" id="pone.0324510.e001g" position="anchor"/><mml:math id="M1" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>) overexposure in critically ill patients with mechanical ventilation and rank the factors, the medical records of 194 mechanically ventilated critically ill patients hospitalized from 12/10/2021&#x02013;06/10/2024 were analyzed. Among 194 critically ill patients, 77.83% were male and 22.17% were female. Univariate analysis showed that oxygenation index (OI), activated partial thromboplastin time (APTT), urea nitrogen (UN), septic shock, heart disease, congestive heart failure (CHF), moderate/severe chronic kidney disease (CKD), etc. were statistically different (<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05). And APTT, OI, CHF and moderate/severe CKD were statistically different in multivariate logistic regression (<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05). The receiver operating characteristic (ROC) curve constructed for APTT and OI was 0.7779 (95% CI [0.708,0.848], <italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001), with a sensitivity and specificity were 72.99% and 71.93%, respectively. The consistency index (<italic toggle="yes">CI</italic>) and consistency ratio (<italic toggle="yes">CR</italic>) of analytic hierarchy process (AHP) was 0.0796 and 0.0885, respectively, which meets the consistency test standard. The contributions of APTT, OI, CHF and moderate to severe CKD to the overexposure of <inline-formula id="pone.0324510.e002"><alternatives><graphic xlink:href="pone.0324510.e002.jpg" id="pone.0324510.e002g" position="anchor"/><mml:math id="M2" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> were 0.0584, 0.1899, 0.1614 and 0.5902, respectively. The overexposure rates of <inline-formula id="pone.0324510.e003"><alternatives><graphic xlink:href="pone.0324510.e003.jpg" id="pone.0324510.e003g" position="anchor"/><mml:math id="M3" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> in patients with moderate/severe CKD and CHF were 95.12% and 95.23%, respectively. With regard to OI, when the cutoff value of OI was less than 245, the <inline-formula id="pone.0324510.e004"><alternatives><graphic xlink:href="pone.0324510.e004.jpg" id="pone.0324510.e004g" position="anchor"/><mml:math id="M4" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub><mml:mtext>&#x000a0;</mml:mtext></mml:mrow></mml:math></alternatives></inline-formula>overexposure rate was 83%, otherwise, the overexposure rate was 60.97%. The risk factors for excessive exposure of <inline-formula id="pone.0324510.e005"><alternatives><graphic xlink:href="pone.0324510.e005.jpg" id="pone.0324510.e005g" position="anchor"/><mml:math id="M5" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> in critically ill patients with mechanical ventilation were ranked as follows: moderate/severe CKD&#x02009;&#x0003e;&#x02009;OI&#x02009;&#x0003e;&#x02009;CHF&#x02009;&#x0003e;&#x02009;APTT.</p></abstract><funding-group><funding-statement>The author(s) received no specific funding for this work.</funding-statement></funding-group><counts><fig-count count="3"/><table-count count="3"/><page-count count="12"/></counts><custom-meta-group><custom-meta id="data-availability"><meta-name>Data Availability</meta-name><meta-value>The datasets used and/or analyzed during the current study available within the manuscript itself.</meta-value></custom-meta></custom-meta-group></article-meta><notes><title>Data Availability</title><p>The datasets used and/or analyzed during the current study available within the manuscript itself.</p></notes></front><body><sec sec-type="intro" id="sec001"><title>Introduction</title><p>Vancomycin is a glycopeptide antibiotic widely used for treating multi-resistant gram-positive bacterial infections, especially those involving methicillin resistant <italic toggle="yes">Staphylococcus aureus</italic> (MRSA) [<xref rid="pone.0324510.ref001" ref-type="bibr">1</xref>&#x02013;<xref rid="pone.0324510.ref006" ref-type="bibr">6</xref>]. However, it is reported that patients with MRSA infection treated with vancomycin suffered from acute kidney injury (AKI) due to vancomycin overexposure [<xref rid="pone.0324510.ref007" ref-type="bibr">7</xref>&#x02013;<xref rid="pone.0324510.ref009" ref-type="bibr">9</xref>]. Therefore, the therapeutic drug monitoring (TDM) implementation of vancomycin is necessary, so as to ensure the safe and effective use of the drug, and avoid excessive or low concentrations leading to sub treatment levels, treatment failure, and toxicity [<xref rid="pone.0324510.ref004" ref-type="bibr">4</xref>].To promote the TDM implementation of vancomycin, the Division of Therapeutic Drug Monitoring of the Chinese Pharmacological Society published an initial clinical practice guideline in 2015 [<xref rid="pone.0324510.ref010" ref-type="bibr">10</xref>]. With concerns about the enhanced resistance of bacteria to vancomycin, clinical practice guidelines have recommended the higher therapeutic levels of vancomycin [<xref rid="pone.0324510.ref011" ref-type="bibr">11</xref>]. Specifically, the area under the curve/minimal inhibitory concentration (AUC/MIC) of vancomycin is regarded as the most accurate reflection of bacterial eradication for patients infected with <italic toggle="yes">Staphylococcus aureus</italic> [<xref rid="pone.0324510.ref012" ref-type="bibr">12</xref>,<xref rid="pone.0324510.ref013" ref-type="bibr">13</xref>]. Unfortunately, the MIC is not generally available for microbial isolates, or for presumed pathogens in the clinical setting. Since AUC is often unavailable, trough levels of antibiotics are commonly used as proxies, though this may be inaccurate [<xref rid="pone.0324510.ref014" ref-type="bibr">14</xref>]. Optimizing vancomycin therapy in the intensive care settings has been the focus of numerous studies in the past [<xref rid="pone.0324510.ref015" ref-type="bibr">15</xref>&#x02013;<xref rid="pone.0324510.ref022" ref-type="bibr">22</xref>]. To reduce the occurrence of therapeutic failure and the development of resistant pathogens, a series of guidelines have been developed [<xref rid="pone.0324510.ref016" ref-type="bibr">16</xref>]. Notably, the guideline indicates the particular vulnerability of critically ill patients, where unpredictable creatinine clearance fluctuations significantly complicate the predictions of <inline-formula id="pone.0324510.e006"><alternatives><graphic xlink:href="pone.0324510.e006.jpg" id="pone.0324510.e006g" position="anchor"/><mml:math id="M6" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>. This pharmacokinetic variability, combined with the altered drug metabolism in critical illness, increases the risk of clinically significant nephrotoxicity, presenting dual challenges in balancing therapeutic efficacy and patient safety [<xref rid="pone.0324510.ref010" ref-type="bibr">10</xref>]. However, clinical observations reveal a significant prevalence of <inline-formula id="pone.0324510.e007"><alternatives><graphic xlink:href="pone.0324510.e007.jpg" id="pone.0324510.e007g" position="anchor"/><mml:math id="M7" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure among critically ill patients undergoing mechanical ventilation.</p><p>This study aimed to investigate the risk factors contributing to this pharmacological phenomenon and systematically examine its clinical implications through retrospective comprehensive analysis of clinical medical records by univariate screening, multivariate logistic regression modeling and AHP among critically ill patients undergoing mechanical ventilation.</p></sec><sec sec-type="materials|methods" id="sec002"><title>Materials and methods</title><sec id="sec003"><title>Patients and data collection</title><p>Clinical observations indicate that numerous mechanically ventilated critically ill patients experience excessive <inline-formula id="pone.0324510.e008"><alternatives><graphic xlink:href="pone.0324510.e008.jpg" id="pone.0324510.e008g" position="anchor"/><mml:math id="M8" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> exposure. To find out the cause of this phenomenon, we began to apply for relevant research and retrospectively collected data of these patients from October to December 2024 (their hospital stay was from 12/10/2021&#x02013;06/10/2024) for analysis. Therefore, 194 critically ill patients who were admitted from 12/10/2021&#x02013;06/10/2024 in the Central People&#x02019;s Hospital of Zhanjiang were enrolled in this study. This study was approved by the Ethical Committee for Research (approval number: KYYS-2023&#x02013;87) and carried out in complete agreement with the pertinent version of the Declaration of Helsinki and all the other relevant regulations.</p><p>All volunteers provided written informed consent before participation in the study. The inclusion criteria were as follows: (1) those aged &#x02265;18 years; (2) requiring vasoactive drugs to maintain blood pressure; (3) vancomycin was used and the time of administration and sampling were recorded accurately; and (4) undergoing mechanical ventilation. The exclusion criteria were shown below: (1) those having serious adverse drug reactions; and (2) un-standard samples. Vancomycin was uniformly infused for 1&#x02009;~&#x02009;3&#x02009;h, and blood samples were collected 0.5&#x02009;h before (trough concentration) and 1&#x02009;h after the end (peak concentration) of administration. Other data such as creatinine clearance were recorded based on the actual test date. The clinical data of 194 critically ill patients were collected and sorted out by using Microsoft Office Excel, and later analyzed by single factor analysis, regression analysis and AHP with SPSS (IBM SPSS Statistics 21), MATLAB (Matlab2012a) and other software.</p><p>AHP is a decision analysis method to solve multi-objective complex problems. This method combines quantitative analysis with qualitative analysis, uses the experience of decision makers to judge the relative importance between the criteria for measuring whether the goal can be achieved, reasonably gives the weight of each criterion for each decision-making scheme, and utilizes the weight to find the order of the advantages and disadvantages of each scheme. AHP is more effectively applied to topics that are difficult to be solved by quantitative methods. The method includes constructing judgment matrix, hierarchical single ranking and consistency test, hierarchical total ranking and one-time test. Consistency check steps of judgment matrix:</p><p>(I) Calculating consistency indicators (<italic toggle="yes">CI</italic>)</p><disp-formula id="pone.0324510.e009">
<alternatives><graphic xlink:href="pone.0324510.e009.jpg" id="pone.0324510.e009g" position="anchor"/><mml:math id="M9" display="block" overflow="scroll"><mml:mrow><mml:mtable columnspacing="" displaystyle="true" rowspacing="3pt"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>C</mml:mi><mml:mi>I</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow><mml:mrow><mml:mtext>'</mml:mtext></mml:mrow></mml:msubsup><mml:mtext>&#x000a0;-&#x000a0;n&#x000a0;</mml:mtext></mml:mrow><mml:mrow><mml:mtext>n&#x000a0;-&#x000a0;1</mml:mtext></mml:mrow></mml:mfrac><mml:mtext>&#x000a0;</mml:mtext></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></alternatives>
<label>(1)</label>
</disp-formula><p>(II) Finding the corresponding average random consistency index (<italic toggle="yes">RI</italic>)</p><p>The <italic toggle="yes">RI</italic> value is to construct 500 sample matrices by the random method: numbers from 1&#x02009;~&#x02009;9 and their reciprocals are randomly extracted to construct a positive reciprocal matrix, then the average value of the maximum eigenvalue <inline-formula id="pone.0324510.e010"><alternatives><graphic xlink:href="pone.0324510.e010.jpg" id="pone.0324510.e010g" position="anchor"/><mml:math id="M10" display="inline" overflow="scroll"><mml:mrow><mml:msubsup><mml:mtext>&#x003bb;</mml:mtext><mml:mrow><mml:mtext>max</mml:mtext></mml:mrow><mml:mrow><mml:mtext>'</mml:mtext></mml:mrow></mml:msubsup></mml:mrow></mml:math></alternatives></inline-formula> is obtained and defined as:</p><disp-formula id="pone.0324510.e011">
<alternatives><graphic xlink:href="pone.0324510.e011.jpg" id="pone.0324510.e011g" position="anchor"/><mml:math id="M11" display="block" overflow="scroll"><mml:mrow><mml:mtable columnspacing="" displaystyle="true" rowspacing="3pt"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>R</mml:mi><mml:mi>I</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:msubsup><mml:mi>&#x003bb;</mml:mi><mml:mrow><mml:mrow><mml:mtext>m</mml:mtext><mml:mi>a</mml:mi><mml:mi>x</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>&#x02032;</mml:mi></mml:mrow></mml:mrow></mml:msubsup><mml:mtext>&#x000a0;</mml:mtext><mml:mrow><mml:mo>&#x02212;</mml:mo><mml:mtext>n</mml:mtext></mml:mrow><mml:mrow/></mml:mrow><mml:mrow><mml:mrow><mml:mtext>n</mml:mtext><mml:mo>&#x02212;</mml:mo><mml:mn>1</mml:mn></mml:mrow></mml:mrow></mml:mfrac><mml:mrow/></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></alternatives>
<label>(2)</label>
</disp-formula><p>This is the Saatty rule.</p><p>(III) Calculating the consistency ratio (<italic toggle="yes">CR</italic>)</p><disp-formula id="pone.0324510.e012">
<alternatives><graphic xlink:href="pone.0324510.e012.jpg" id="pone.0324510.e012g" position="anchor"/><mml:math id="M12" display="block" overflow="scroll"><mml:mrow><mml:mtable columnspacing="" displaystyle="true" rowspacing="3pt"><mml:mtr><mml:mtd columnalign="right"><mml:mrow><mml:mi>C</mml:mi><mml:mi>R</mml:mi><mml:mo>=</mml:mo></mml:mrow><mml:mfrac><mml:mrow><mml:mrow><mml:mi>C</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:mrow><mml:mrow><mml:mrow><mml:mi>R</mml:mi><mml:mi>I</mml:mi></mml:mrow></mml:mrow></mml:mfrac></mml:mtd></mml:mtr></mml:mtable></mml:mrow></mml:math></alternatives>
<label>(3)</label>
</disp-formula><p>When <italic toggle="yes">CR</italic>&#x02009;&#x0003c;&#x02009;0.10, it is considered that the consistency of the judgment matrix is acceptable, otherwise the judgment matrix should be properly corrected.</p></sec><sec id="sec004"><title>Statistical analysis</title><p>Statistical analyses included Student&#x02019;s t-tests for mean comparisons and logistic regression for multivariate analysis, with a significance threshold of <italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05.</p></sec></sec><sec sec-type="results" id="sec005"><title>Results</title><sec id="sec006"><title>General clinical data of patients</title><p>A total of 194 critically ill patients undergoing mechanical ventilation were included, including 151 males (77.83%) and 43 females (22.17%). The age, body weight and APAPHE II score of the patients were 63.86&#x02009;&#x000b1;&#x02009;14.39, 64.22&#x02009;&#x000b1;&#x02009;11.80 and 20.80&#x02009;&#x000b1;&#x02009;6.64, respectively. The proportion of critically ill patients requiring vasoactive agents was 59.79%; to be specific, the proportions were 64.23% in the vancomycin overexposure group and 49.12% in the compliant group, and there was no statistical difference between the two groups (<italic toggle="yes">P&#x02009;</italic>&#x0003e;&#x02009;0.05). The baseline data of the enrolled patients are shown in <xref rid="pone.0324510.t001" ref-type="table">Table 1</xref>.</p><table-wrap position="float" id="pone.0324510.t001"><object-id pub-id-type="doi">10.1371/journal.pone.0324510.t001</object-id><label>Table 1</label><caption><title>Demographic, Laboratory Variables and clinical data.</title></caption><alternatives><graphic xlink:href="pone.0324510.t001" id="pone.0324510.t001g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Characteristic</th><th align="left" rowspan="1" colspan="1"/><th align="left" rowspan="1" colspan="1">Total (194)</th><th align="left" rowspan="1" colspan="1">Compliant group (57)</th><th align="left" rowspan="1" colspan="1">Overexposure group (137)</th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Age, years</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">63.86&#x02009;&#x000b1;&#x02009;14.39</td><td align="left" rowspan="1" colspan="1">59.79&#x02009;&#x000b1;&#x02009;13.54</td><td align="left" rowspan="1" colspan="1">65.55&#x02009;&#x000b1;&#x02009;14.45</td><td align="left" rowspan="1" colspan="1">0.791</td></tr><tr><td align="left" rowspan="1" colspan="1">Male, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">151(77.83%)</td><td align="left" rowspan="1" colspan="1">50(87.72%)</td><td align="left" rowspan="1" colspan="1">101(73.72%)</td><td align="left" rowspan="1" colspan="1">0.051</td></tr><tr><td align="left" rowspan="1" colspan="1">Weight, kg</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">64.22&#x02009;&#x000b1;&#x02009;11.80</td><td align="left" rowspan="1" colspan="1">67.33&#x02009;&#x000b1;&#x02009;12.08</td><td align="left" rowspan="1" colspan="1">62.93&#x02009;&#x000b1;&#x02009;11.48</td><td align="left" rowspan="1" colspan="1">0.931</td></tr><tr><td align="left" rowspan="1" colspan="1">Albumin(g/L)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">31.59&#x02009;&#x000b1;&#x02009;6.09</td><td align="left" rowspan="1" colspan="1">32.34&#x02009;&#x000b1;&#x02009;6.02</td><td align="left" rowspan="1" colspan="1">31.27&#x02009;&#x000b1;&#x02009;6.12</td><td align="left" rowspan="1" colspan="1">0.996</td></tr><tr><td align="left" rowspan="1" colspan="1">APAPHE II score</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20.80&#x02009;&#x000b1;&#x02009;6.64</td><td align="left" rowspan="1" colspan="1">19.42&#x02009;&#x000b1;&#x02009;6.81</td><td align="left" rowspan="1" colspan="1">21.38&#x02009;&#x000b1;&#x02009;6.51</td><td align="left" rowspan="1" colspan="1">0.539</td></tr><tr><td align="left" rowspan="1" colspan="1">WBC (x10<sup>9</sup>/L)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">13.70[9.42, 18.64]</td><td align="left" rowspan="1" colspan="1">14.30[10.75, 19.50]</td><td align="left" rowspan="1" colspan="1">13.10[8.68, 18.61]</td><td align="left" rowspan="1" colspan="1">0.242</td></tr><tr><td align="left" rowspan="1" colspan="1">PLT (x10<sup>9</sup>/L)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">176.00[82.50, 281.00]</td><td align="left" rowspan="1" colspan="1">185.00[108.00, 286.00]</td><td align="left" rowspan="1" colspan="1">167.00[78.00, 280.50]</td><td align="left" rowspan="1" colspan="1">0.146</td></tr><tr><td align="left" rowspan="1" colspan="1">PCT (&#x003bc;g/L)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.49[0.67, 14.84]</td><td align="left" rowspan="1" colspan="1">1.06[0.39, 4.02]</td><td align="left" rowspan="1" colspan="1">4.06[0.74, 25.55]</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">PT (S)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">15.05[13.90, 17.90]</td><td align="left" rowspan="1" colspan="1">14.40[13.30, 15.95]</td><td align="left" rowspan="1" colspan="1">15.50[13.90, 18.70]</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">APTT (S)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">36.35[32.15, 42.20]</td><td align="left" rowspan="1" colspan="1">32.70[29.15, 37.20]</td><td align="left" rowspan="1" colspan="1">37.00[33.95, 43.60]</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">INR</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.22[1.12, 1.44]</td><td align="left" rowspan="1" colspan="1">1.16[1.08, 1.27]</td><td align="left" rowspan="1" colspan="1">1.26[1.14, 1.50]</td><td align="left" rowspan="1" colspan="1">0.002</td></tr><tr><td align="left" rowspan="1" colspan="1">ALT (U/L)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">30.37[13.92, 72.42]</td><td align="left" rowspan="1" colspan="1">36.80[17.95, 58.15]</td><td align="left" rowspan="1" colspan="1">28.30[13.30, 74.70]</td><td align="left" rowspan="1" colspan="1">0.374</td></tr><tr><td align="left" rowspan="1" colspan="1">AST (U/L)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">50.40[28.00, 106.39]</td><td align="left" rowspan="1" colspan="1">51.00[24.95, 90.35]</td><td align="left" rowspan="1" colspan="1">50.00[28.65, 132.00]</td><td align="left" rowspan="1" colspan="1">0.533</td></tr><tr><td align="left" rowspan="1" colspan="1">TBIL (&#x003bc;mol/L)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">13.95[8.30, 26.10]</td><td align="left" rowspan="1" colspan="1">13.90[8.30, 22.10]</td><td align="left" rowspan="1" colspan="1">14.00[8.30, 26.90]</td><td align="left" rowspan="1" colspan="1">0.628</td></tr><tr><td align="left" rowspan="1" colspan="1">UN (mmol/L)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">11.71[7.23, 18.94]</td><td align="left" rowspan="1" colspan="1">8.84[5.40, 15.42]</td><td align="left" rowspan="1" colspan="1">12.76[7.80, 20.30]</td><td align="left" rowspan="1" colspan="1">0.004</td></tr><tr><td align="left" rowspan="1" colspan="1">CR (&#x003bc;mol/L)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">103.00[67.00, 157.65]</td><td align="left" rowspan="1" colspan="1">97.00[67.00, 136.71]</td><td align="left" rowspan="1" colspan="1">108.30[62.59, 170.00]</td><td align="left" rowspan="1" colspan="1">0.370</td></tr><tr><td align="left" rowspan="1" colspan="1">eGFR(ml/min/1.73m<sup>2</sup>)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">60.37[36.23, 97.43]</td><td align="left" rowspan="1" colspan="1">68.15[43.86, 97.84]</td><td align="left" rowspan="1" colspan="1">58.68[32.08, 96.83]</td><td align="left" rowspan="1" colspan="1">0.228</td></tr><tr><td align="left" rowspan="1" colspan="1">OI</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">219.11[163.12, 294.50]</td><td align="left" rowspan="1" colspan="1">262.50[172.67, 322.16]</td><td align="left" rowspan="1" colspan="1">204.00[154.00, 283.33]</td><td align="left" rowspan="1" colspan="1">0.003</td></tr><tr><td align="left" rowspan="1" colspan="1">MAP</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">78.00[67.00, 85.00]</td><td align="left" rowspan="1" colspan="1">81.00[74.50, 85.00]</td><td align="left" rowspan="1" colspan="1">78.00[67.00, 84.00]</td><td align="left" rowspan="1" colspan="1">0.063</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>Non-infectious treatment during hospitalization</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Invasive respiratory mechanical ventilation</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">162.00(83.50%)</td><td align="left" rowspan="1" colspan="1">47.00(82.45%)</td><td align="left" rowspan="1" colspan="1">115.00(83.94%)</td><td align="left" rowspan="1" colspan="1">0.800</td></tr><tr><td align="left" rowspan="1" colspan="1">Vasoactive agents, n (%)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">116.00(59.79%)</td><td align="left" rowspan="1" colspan="1">28.00(49.12%)</td><td align="left" rowspan="1" colspan="1">88.00(64.23%)</td><td align="left" rowspan="1" colspan="1">0.051</td></tr><tr><td align="left" rowspan="1" colspan="1">ECMO</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.00(2.03%)</td><td align="left" rowspan="1" colspan="1">0.00(0%)</td><td align="left" rowspan="1" colspan="1">4.00(2.92%)</td><td align="left" rowspan="1" colspan="1">0.454</td></tr><tr><td align="left" rowspan="1" colspan="1">CRRT</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">57.00(29.38%)</td><td align="left" rowspan="1" colspan="1">11.00(19.30%)</td><td align="left" rowspan="1" colspan="1">46.00(33.58%)</td><td align="left" rowspan="1" colspan="1">0.047</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>Anti-infection program during hospitalization</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Combined antifungal drugs</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">35.00(18.04%)</td><td align="left" rowspan="1" colspan="1">7.00(12.28%)</td><td align="left" rowspan="1" colspan="1">28.00(20.43%)</td><td align="left" rowspan="1" colspan="1">0.178</td></tr><tr><td align="left" rowspan="1" colspan="1">Antibiotic monotherapy</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">8.00(4.12%)</td><td align="left" rowspan="1" colspan="1">2.00(3.51%)</td><td align="left" rowspan="1" colspan="1">6.00(4.38%)</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="6" colspan="1">Types of combined antibiotics</td><td align="left" rowspan="1" colspan="1">MEM</td><td align="left" rowspan="1" colspan="1">52.00(26.80%)</td><td align="left" rowspan="1" colspan="1">17.00(29.82%)</td><td align="left" rowspan="1" colspan="1">35.00(25.55%)</td><td align="left" rowspan="6" colspan="1"/></tr><tr><td align="left" rowspan="1" colspan="1">IPM</td><td align="left" rowspan="1" colspan="1">79.00(40.72%)</td><td align="left" rowspan="1" colspan="1">17.00(29.82%)</td><td align="left" rowspan="1" colspan="1">62.00(45.25%)</td></tr><tr><td align="left" rowspan="1" colspan="1">TZP</td><td align="left" rowspan="1" colspan="1">25.00(12.88%)</td><td align="left" rowspan="1" colspan="1">12.00(21.05%)</td><td align="left" rowspan="1" colspan="1">13.00(9.49%)</td></tr><tr><td align="left" rowspan="1" colspan="1">POL</td><td align="left" rowspan="1" colspan="1">3.00(1.55%)</td><td align="left" rowspan="1" colspan="1">0.00(0%)</td><td align="left" rowspan="1" colspan="1">3.00(2.19%)</td></tr><tr><td align="left" rowspan="1" colspan="1">VOR</td><td align="left" rowspan="1" colspan="1">8.00(4.12%)</td><td align="left" rowspan="1" colspan="1">1.00(1.75%)</td><td align="left" rowspan="1" colspan="1">7.00(5.11%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Others</td><td align="left" rowspan="1" colspan="1">27.00(13.92%)</td><td align="left" rowspan="1" colspan="1">10.00(17.54%)</td><td align="left" rowspan="1" colspan="1">17.00(12.41%)</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>Infection sites</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Pulmonary infection</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">182.00(93.81%)</td><td align="left" rowspan="1" colspan="1">52.00(91.23%)</td><td align="left" rowspan="1" colspan="1">130.00(94.89%)</td><td align="left" rowspan="1" colspan="1">0.524</td></tr><tr><td align="left" rowspan="1" colspan="1">Septic shock</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">85.00(43.81%)</td><td align="left" rowspan="1" colspan="1">17.00(29.82%)</td><td align="left" rowspan="1" colspan="1">68.00(49.63%)</td><td align="left" rowspan="1" colspan="1">0.011</td></tr><tr><td align="left" rowspan="1" colspan="1">Bloodstream infection</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">34.00(17.52%)</td><td align="left" rowspan="1" colspan="1">8.00(14.03%)</td><td align="left" rowspan="1" colspan="1">26.00(18.98%)</td><td align="left" rowspan="1" colspan="1">0.409</td></tr><tr><td align="left" rowspan="1" colspan="1">Abdominal infection</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">37.00(19.07%)</td><td align="left" rowspan="1" colspan="1">11.00(19.29%)</td><td align="left" rowspan="1" colspan="1">26.00(18.98%)</td><td align="left" rowspan="1" colspan="1">0.959</td></tr><tr><td align="left" rowspan="1" colspan="1">Intestinal infection</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">8.00(4.12%)</td><td align="left" rowspan="1" colspan="1">0.00(0%)</td><td align="left" rowspan="1" colspan="1">8.00(5.84%)</td><td align="left" rowspan="1" colspan="1">0.142</td></tr><tr><td align="left" rowspan="1" colspan="1">Central nervous system infection</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">16.00(8.25%)</td><td align="left" rowspan="1" colspan="1">8.00(14.03%)</td><td align="left" rowspan="1" colspan="1">8.00(5.84%)</td><td align="left" rowspan="1" colspan="1">0.109</td></tr><tr><td align="left" rowspan="1" colspan="1">Skin and soft tissue infection</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">11.00(5.67%)</td><td align="left" rowspan="1" colspan="1">4.00(7.01%)</td><td align="left" rowspan="1" colspan="1">7.00(5.11%)</td><td align="left" rowspan="1" colspan="1">0.855</td></tr><tr><td align="left" rowspan="1" colspan="1">Urinary system infection</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18.00(9.28%)</td><td align="left" rowspan="1" colspan="1">3.00(5.25%)</td><td align="left" rowspan="1" colspan="1">15.00(10.95%)</td><td align="left" rowspan="1" colspan="1">0.214</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocarditis/endocarditis</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">8.00(4.12%)</td><td align="left" rowspan="1" colspan="1">1.00(1.75%)</td><td align="left" rowspan="1" colspan="1">7.00(5.11%)</td><td align="left" rowspan="1" colspan="1">0.500</td></tr><tr><td align="left" rowspan="1" colspan="1">Pancreatitis</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.00(1.55%)</td><td align="left" rowspan="1" colspan="1">2.00(3.51%)</td><td align="left" rowspan="1" colspan="1">1.00(0.73%)</td><td align="left" rowspan="1" colspan="1">0.429</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>Previous history</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospitalization history(&#x0003c;90d)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">95.00(48.97%)</td><td align="left" rowspan="1" colspan="1">26.00(45.61%)</td><td align="left" rowspan="1" colspan="1">69.00(50.36%)</td><td align="left" rowspan="1" colspan="1">0.547</td></tr><tr><td align="left" rowspan="1" colspan="1">Surgery</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">60.00(30.93%)</td><td align="left" rowspan="1" colspan="1">16.00(28.07%)</td><td align="left" rowspan="1" colspan="1">44.00(32.12%)</td><td align="left" rowspan="1" colspan="1">0.579</td></tr><tr><td align="left" rowspan="1" colspan="1">History of antibiotics (&#x0003c;90d)</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">63.00(32.47%)</td><td align="left" rowspan="1" colspan="1">18.00(31.58%)</td><td align="left" rowspan="1" colspan="1">45.00(32.85%)</td><td align="left" rowspan="1" colspan="1">0.838</td></tr><tr><td align="left" rowspan="1" colspan="1">Immunosuppressive condition</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.00(2.06%)</td><td align="left" rowspan="1" colspan="1">0.00(0%)</td><td align="left" rowspan="1" colspan="1">4.00(2.92%)</td><td align="left" rowspan="1" colspan="1">0.450</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>Combined underlying diseases</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypertension</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">95.00(48.97%)</td><td align="left" rowspan="1" colspan="1">29.00(50.88%)</td><td align="left" rowspan="1" colspan="1">66.00(48.17%)</td><td align="left" rowspan="1" colspan="1">0.732</td></tr><tr><td align="left" rowspan="1" colspan="1">Hyperthyroidism</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">4.00(2.06%)</td><td align="left" rowspan="1" colspan="1">1.00(1.75%)</td><td align="left" rowspan="1" colspan="1">3.00(2.19%)</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Hypothyroidism</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00(0.52%)</td><td align="left" rowspan="1" colspan="1">1.00(1.75%)</td><td align="left" rowspan="1" colspan="1">0.00(0%)</td><td align="left" rowspan="1" colspan="1">0.650</td></tr><tr><td align="left" rowspan="1" colspan="1">Diabetes</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">38.00(19.59%)</td><td align="left" rowspan="1" colspan="1">9.00(15.79%)</td><td align="left" rowspan="1" colspan="1">29.00(21.17%)</td><td align="left" rowspan="1" colspan="1">0.114</td></tr><tr><td align="left" rowspan="1" colspan="1">Peptic ulcer</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">15.00(7.73%)</td><td align="left" rowspan="1" colspan="1">4.00(7.01%)</td><td align="left" rowspan="1" colspan="1">11.00(8.03%)</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic obstructive pulmonary disease/ asthma</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">18.00(9.28%)</td><td align="left" rowspan="1" colspan="1">4.00(7.01%)</td><td align="left" rowspan="1" colspan="1">14.00(10.22%)</td><td align="left" rowspan="1" colspan="1">0.484</td></tr><tr><td align="left" rowspan="1" colspan="1">Heart disease</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">44.00(22.68%)</td><td align="left" rowspan="1" colspan="1">7.00(12.28%)</td><td align="left" rowspan="1" colspan="1">37.00(27.01%)</td><td align="left" rowspan="1" colspan="1">0.026</td></tr><tr><td align="left" rowspan="1" colspan="1">Myocardial infarction</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">12.00(6.19%)</td><td align="left" rowspan="1" colspan="1">4.00(7.02%)</td><td align="left" rowspan="1" colspan="1">8.00(5.84%)</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Congestive heart failure</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">21.00(10.82%)</td><td align="left" rowspan="1" colspan="1">2.00(3.51%)</td><td align="left" rowspan="1" colspan="1">19.00(13.87%)</td><td align="left" rowspan="1" colspan="1">0.034</td></tr><tr><td align="left" rowspan="1" colspan="1">Peripheral arterial disease</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">1.00(0.52%)</td><td align="left" rowspan="1" colspan="1">0.00(0%)</td><td align="left" rowspan="1" colspan="1">1.00(0.73%)</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Cerebrovascular disease or TIA</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">40.00(20.62%)</td><td align="left" rowspan="1" colspan="1">10.00(17.54%)</td><td align="left" rowspan="1" colspan="1">30.00(21.89%)</td><td align="left" rowspan="1" colspan="1">0.495</td></tr><tr><td align="left" rowspan="1" colspan="1">Hemiplegia</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.00(1.55%)</td><td align="left" rowspan="1" colspan="1">1.00(1.75%)</td><td align="left" rowspan="1" colspan="1">2.00(1.46%)</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Dementia/Alzheimer &#x02018;s disease</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">2.00(1.03%)</td><td align="left" rowspan="1" colspan="1">1.00(1.75%)</td><td align="left" rowspan="1" colspan="1">1.00(0.73%)</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Rheumatoid or connective tissue disease</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.00(1.55%)</td><td align="left" rowspan="1" colspan="1">0.00(0%)</td><td align="left" rowspan="1" colspan="1">3.00(2.19%)</td><td align="left" rowspan="1" colspan="1">0.626</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate/severe CKD</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">41.00(21.13%)</td><td align="left" rowspan="1" colspan="1">3.00(5.26%)</td><td align="left" rowspan="1" colspan="1">38.00(27.73%)</td><td align="left" rowspan="1" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">Leukemia</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.00(1.55%)</td><td align="left" rowspan="1" colspan="1">1.00(1.75%)</td><td align="left" rowspan="1" colspan="1">2.00(1.46%)</td><td align="left" rowspan="1" colspan="1">1.000</td></tr><tr><td align="left" rowspan="1" colspan="1">Lymphoma</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">3.00(1.55%)</td><td align="left" rowspan="1" colspan="1">0.00(0%)</td><td align="left" rowspan="1" colspan="1">3.00(2.19%)</td><td align="left" rowspan="1" colspan="1">0.626</td></tr><tr><td align="left" colspan="6" rowspan="1">
<bold>Prognosis and outcome</bold>
</td></tr><tr><td align="left" rowspan="1" colspan="1">ICU</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">176.00(90.72%)</td><td align="left" rowspan="1" colspan="1">54.00(94.73%)</td><td align="left" rowspan="1" colspan="1">122.00(89.05%)</td><td align="left" rowspan="1" colspan="1">0.214</td></tr><tr><td align="left" rowspan="1" colspan="1">Duration of ICU</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">17.37&#x02009;&#x000b1;&#x02009;10.57</td><td align="left" rowspan="1" colspan="1">19.61&#x02009;&#x000b1;&#x02009;9.66</td><td align="left" rowspan="1" colspan="1">16.44&#x02009;&#x000b1;&#x02009;10.82</td><td align="left" rowspan="1" colspan="1">0.212</td></tr><tr><td align="left" rowspan="3" colspan="1">Outcome (0, 1 and 2)</td><td align="left" rowspan="1" colspan="1">0</td><td align="left" rowspan="1" colspan="1">87.00(44.84%)</td><td align="left" rowspan="1" colspan="1">31.00(54.38%)</td><td align="left" rowspan="1" colspan="1">56.00(40.87%)</td><td align="left" rowspan="3" colspan="1">&#x0003c;0.001</td></tr><tr><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">30.00(15.46%)</td><td align="left" rowspan="1" colspan="1">3.00(5.26%)</td><td align="left" rowspan="1" colspan="1">27.00(29.71%)</td></tr><tr><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">76.00(39.17%)</td><td align="left" rowspan="1" colspan="1">23.00(40.35%)</td><td align="left" rowspan="1" colspan="1">53.00(38.68%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Hospital days</td><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1">20.35&#x02009;&#x000b1;&#x02009;9.77</td><td align="left" rowspan="1" colspan="1">21.17&#x02009;&#x000b1;&#x02009;9.21</td><td align="left" rowspan="1" colspan="1">20.01&#x02009;&#x000b1;&#x02009;10.02</td><td align="left" rowspan="1" colspan="1">0.365</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t001fn001"><p><bold>Note:</bold> WBC: White blood cell count; PLT: Platelet count; OI: Oxygenation index; MAP: Mean arterial pressure; CR: Creatinine; TBIL: Total bilirubin; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; MEM: Meropenem; IPM: Imipenem; TZP: Piperacillin/Tazobactam; VOR: Voriconazole; POL: Polymyxin; PCT: Procalcitonin; APTT: Activated partial thromboplastin time; INR: International normalized ratio; UN: Urea nitrogen; OI: Oxygenation index; CRRT: Continuous renal replacement therapy; CKD: chronic kidney disease; 0&#x02009;=&#x02009;cured/improved discharge,1&#x02009;=&#x02009;died, 2&#x02009;=&#x02009;gave up treatment and discharged automatically.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec007"><title>Univariate analysis</title><p>Univariate analysis revealed statistically significant differences (P&#x02009;&#x0003c;&#x02009;0.05) in procalcitonin (PCT), prothrombin time (PT), APTT, international normalized ratio (INR), UN, OI, continuous renal replacement therapy (CRRT), septic shock, heart disease, CHF and moderate/severe CKD between the vancomycin overexposure and compliant groups.</p><p>To start with, as shown in <xref rid="pone.0324510.g001" ref-type="fig">Fig 1A</xref>, almost all patients who died during hospitalization occurred in the <inline-formula id="pone.0324510.e013"><alternatives><graphic xlink:href="pone.0324510.e013.jpg" id="pone.0324510.e013g" position="anchor"/><mml:math id="M13" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure group, while mortality in the <inline-formula id="pone.0324510.e014"><alternatives><graphic xlink:href="pone.0324510.e014.jpg" id="pone.0324510.e014g" position="anchor"/><mml:math id="M14" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> compliant group was not significant. Secondly, the patients of the <inline-formula id="pone.0324510.e015"><alternatives><graphic xlink:href="pone.0324510.e015.jpg" id="pone.0324510.e015g" position="anchor"/><mml:math id="M15" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure group generally had high PCT, which indicated more severe infection than the compliant group (4.06 vs 1.06, <italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001, <xref rid="pone.0324510.g001" ref-type="fig">Fig 1B</xref>). Thirdly, patients with CHF were more likely to occur in the <inline-formula id="pone.0324510.e016"><alternatives><graphic xlink:href="pone.0324510.e016.jpg" id="pone.0324510.e016g" position="anchor"/><mml:math id="M16" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure group compared with the compliant group (13.87% vs 3.51%, <italic toggle="yes">P</italic>&#x02009;=&#x02009;0.034, <xref rid="pone.0324510.g001" ref-type="fig">Fig 1C</xref>). Fourthly, the patients with moderate/severe CKD were more likely to occur in the <inline-formula id="pone.0324510.e017"><alternatives><graphic xlink:href="pone.0324510.e017.jpg" id="pone.0324510.e017g" position="anchor"/><mml:math id="M17" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure group relative to the compliant group (27.73% vs 5.26%, <italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001, <xref rid="pone.0324510.g001" ref-type="fig">Fig 1D</xref>).</p><fig position="float" id="pone.0324510.g001"><object-id pub-id-type="doi">10.1371/journal.pone.0324510.g001</object-id><label>Fig 1</label><caption><title>Visualization of critical clinical determinants.</title><p><bold>(A)</bold> Temporal dynamics of ICU duration (black solid line) versus time-to-mortality post-admission (red solid dots) and vancomycin compliant/overexposure curve (blue solid dots, 0&#x02009;=&#x02009;Compliant group, 1&#x02009;=&#x02009;Overexposure group). <bold>(B)</bold> The PCT trajectory (red solid dots) and vancomycin compliant/overexposure curve (blue solid dots, 0&#x02009;=&#x02009;Compliant group, 1&#x02009;=&#x02009;Overexposure group); <bold>(C)</bold> Congestive heart failure comorbidity status (red dots: 0&#x02009;=&#x02009;absent, 1&#x02009;=&#x02009;present) plotted against vancomycin exposure levels (blue solid dots, 0&#x02009;=&#x02009;Compliant group, 1&#x02009;=&#x02009;Overexposure group), highlighting cardiorenal toxicity associations. <bold>(D)</bold> Moderate/severe CKD progression (red dots: 0&#x02009;=&#x02009;non-CKD, 1&#x02009;=&#x02009;CKD stage 3-5) correlated with vancomycin exposure (blue solid dots, 0&#x02009;=&#x02009;Compliant group, 1&#x02009;=&#x02009;Overexposure group), quantifying nephrotoxicity risks across renal function strata.</p></caption><graphic xlink:href="pone.0324510.g001" position="float"/></fig><p>(<bold>Note:</bold> The data were analyzed by SPSS (IBM SPSS Statistics 21). Compliant group: 10&#x003bc;g/mL &#x02264; <inline-formula id="pone.0324510.e018"><alternatives><graphic xlink:href="pone.0324510.e018.jpg" id="pone.0324510.e018g" position="anchor"/><mml:math id="M18" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> &#x02264; 20&#x003bc;g/mL; Overexposure group: <inline-formula id="pone.0324510.e019"><alternatives><graphic xlink:href="pone.0324510.e019.jpg" id="pone.0324510.e019g" position="anchor"/><mml:math id="M19" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> &#x0003e; 20&#x003bc;g/mL).</p></sec><sec id="sec008"><title>Multiple logistic regression</title><p>The factors satisfying <italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05 in univariate analysis were included in multivariate logistic regression analysis. After adjusting for confounding factors, the results showed that PCT, INR, UN, CRRT and septic shock had no significant effect on predicting the <inline-formula id="pone.0324510.e020"><alternatives><graphic xlink:href="pone.0324510.e020.jpg" id="pone.0324510.e020g" position="anchor"/><mml:math id="M20" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure (<italic toggle="yes">P &#x0003e;</italic> 0.05). There were significant differences in APTT, OI, CHF and moderate/severe CKD factors in predicting <inline-formula id="pone.0324510.e021"><alternatives><graphic xlink:href="pone.0324510.e021.jpg" id="pone.0324510.e021g" position="anchor"/><mml:math id="M21" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> was statistically different (<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05) (<xref rid="pone.0324510.t002" ref-type="table">Table 2</xref>), and they were more likely to induce <inline-formula id="pone.0324510.e022"><alternatives><graphic xlink:href="pone.0324510.e022.jpg" id="pone.0324510.e022g" position="anchor"/><mml:math id="M22" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure.</p><table-wrap position="float" id="pone.0324510.t002"><object-id pub-id-type="doi">10.1371/journal.pone.0324510.t002</object-id><label>Table 2</label><caption><title>Multivariate logistic regression analysis of factors affecting vancomycin serum trough concentration overexposure.</title></caption><alternatives><graphic xlink:href="pone.0324510.t002" id="pone.0324510.t002g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">Variables</th><th align="left" rowspan="1" colspan="1">
<italic toggle="yes">OR</italic>
</th><th align="left" rowspan="1" colspan="1">95%<italic toggle="yes">CI</italic></th><th align="left" rowspan="1" colspan="1"><italic toggle="yes">P</italic>-value</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">PCT</td><td align="left" rowspan="1" colspan="1">1.002</td><td align="left" rowspan="1" colspan="1">[0.996, 1.014]</td><td align="left" rowspan="1" colspan="1">0.637</td></tr><tr><td align="left" rowspan="1" colspan="1">APTT</td><td align="left" rowspan="1" colspan="1">1.052</td><td align="left" rowspan="1" colspan="1">[1.004, 1.110]</td><td align="left" rowspan="1" colspan="1">0.046</td></tr><tr><td align="left" rowspan="1" colspan="1">INR</td><td align="left" rowspan="1" colspan="1">1.496</td><td align="left" rowspan="1" colspan="1">[0.756, 4.626]</td><td align="left" rowspan="1" colspan="1">0.392</td></tr><tr><td align="left" rowspan="1" colspan="1">UN</td><td align="left" rowspan="1" colspan="1">1.027</td><td align="left" rowspan="1" colspan="1">[0.978, 1.085]</td><td align="left" rowspan="1" colspan="1">0.311</td></tr><tr><td align="left" rowspan="1" colspan="1">OI</td><td align="left" rowspan="1" colspan="1">0.995</td><td align="left" rowspan="1" colspan="1">[0.991, 0.999]</td><td align="left" rowspan="1" colspan="1">0.033</td></tr><tr><td align="left" rowspan="1" colspan="1">CRRT</td><td align="left" rowspan="1" colspan="1">0.964</td><td align="left" rowspan="1" colspan="1">[0.374, 2.486]</td><td align="left" rowspan="1" colspan="1">0.940</td></tr><tr><td align="left" rowspan="1" colspan="1">Congestive heart failure</td><td align="left" rowspan="1" colspan="1">5.023</td><td align="left" rowspan="1" colspan="1">[1.033, 24.430]</td><td align="left" rowspan="1" colspan="1">0.046</td></tr><tr><td align="left" rowspan="1" colspan="1">Moderate/severe CKD</td><td align="left" rowspan="1" colspan="1">5.187</td><td align="left" rowspan="1" colspan="1">[1.442, 18.663]</td><td align="left" rowspan="1" colspan="1">0.012</td></tr><tr><td align="left" rowspan="1" colspan="1">Septic shock</td><td align="left" rowspan="1" colspan="1">1.851</td><td align="left" rowspan="1" colspan="1">[0.845, 4.053]</td><td align="left" rowspan="1" colspan="1">0.124</td></tr></tbody></table></alternatives><table-wrap-foot><fn id="t002fn001"><p><bold>Note:</bold> PCT: Procalcitonin; APTT: Activated partial thromboplastin time; INR: International normalized ratio; UN: Urea nitrogen; OI: Oxygenation index; CRRT: Continuous renal replacement therapy; CKD: chronic kidney disease.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec009"><title>ROC curve analysis</title><p>The AUC corresponding to the ROC curve constructed for APTT and OI was 0.7779 (95% CI [0.708,0.848], <italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001). The sensitivity and specificity were 72.99% and 71.93%, respectively. The maximum Youden index of APTT was 0.370, and the optimal cutoff value of APTT was 33.65&#x02009;s. When APTT&#x02009;&#x0003e;&#x02009;33.65s, for every unit increase in APTT, the possibility of <inline-formula id="pone.0324510.e023"><alternatives><graphic xlink:href="pone.0324510.e023.jpg" id="pone.0324510.e023g" position="anchor"/><mml:math id="M23" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure increased by 1.052 times. The maximum value of the Youden index of OI was -0.2637, and the optimal cutoff value of OI was 245.5. When OI&#x02009;&#x0003c;&#x02009;245.5, the risk of <inline-formula id="pone.0324510.e024"><alternatives><graphic xlink:href="pone.0324510.e024.jpg" id="pone.0324510.e024g" position="anchor"/><mml:math id="M24" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> exposure increased by 0.995 times. (<xref rid="pone.0324510.g002" ref-type="fig">Fig 2</xref>)</p><fig position="float" id="pone.0324510.g002"><object-id pub-id-type="doi">10.1371/journal.pone.0324510.g002</object-id><label>Fig 2</label><caption><title>The ROC curve for APTT and OI to evaluate the accuracy of</title><p><inline-formula id="pone.0324510.e025"><alternatives><graphic xlink:href="pone.0324510.e025" id="pone.0324510.e025g" position="anchor"/><mml:math id="M25" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula>
<bold>overexposure.</bold></p></caption><graphic xlink:href="pone.0324510.g002" position="float"/></fig><p>The overexposure rates of <inline-formula id="pone.0324510.e026"><alternatives><graphic xlink:href="pone.0324510.e026.jpg" id="pone.0324510.e026g" position="anchor"/><mml:math id="M26" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> in patients with moderate/severe CKD and CHF were 39/41(95.12%) and 20/21(95.23%), respectively. With regard to OI, when the cutoff value of OI was less than 245, the <inline-formula id="pone.0324510.e027"><alternatives><graphic xlink:href="pone.0324510.e027.jpg" id="pone.0324510.e027g" position="anchor"/><mml:math id="M27" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure rate was 93/112 (83%); otherwise, the overexposure rate was 50/82(60.97%). For APTT, the overexposure rate was 107/131(81.67%) when the cutoff value of APTT was more than 33.65&#x02009;s; otherwise, the overexposure rate was 32/63(50.79%).</p></sec><sec id="sec010"><title>Principle of AHP</title><p>Based on drug labeling and literature analyzing the adverse drug reactions induced by three types of anti-MRSA drugs[<xref rid="pone.0324510.ref023" ref-type="bibr">23</xref>]. According to the idea of AHP and Saatty criterion, the weight judgment matrix of these factors on <inline-formula id="pone.0324510.e028"><alternatives><graphic xlink:href="pone.0324510.e028.jpg" id="pone.0324510.e028g" position="anchor"/><mml:math id="M28" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> was obtained, and the judgment matrix A of the criterion layer is as follows.</p><disp-formula id="pone.0324510.e029">
<alternatives><graphic xlink:href="pone.0324510.e029.jpg" id="pone.0324510.e029g" position="anchor"/><mml:math id="M29" display="block" overflow="scroll"><mml:mrow><mml:mtext>A=&#x000a0;</mml:mtext><mml:mo>[</mml:mo><mml:mtable><mml:mtr><mml:mtd><mml:mtext>&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:mtable><mml:mtr><mml:mtd><mml:mn>1</mml:mn><mml:mtext>&#x000a0;</mml:mtext></mml:mtd><mml:mtd><mml:mtext>&#x000a0;</mml:mtext><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>3</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>3</mml:mn><mml:mtext>&#x000a0;</mml:mtext></mml:mtd><mml:mtd><mml:mtext>&#x000a0;</mml:mtext><mml:mn>1</mml:mn></mml:mtd></mml:mtr></mml:mtable><mml:mtext>&#x000a0;&#x000a0;&#x000a0;</mml:mtext></mml:mtd><mml:mtd><mml:mtext>&#x000a0;&#x000a0;</mml:mtext><mml:mtable><mml:mtr><mml:mtd><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>5</mml:mn></mml:mtd><mml:mtd><mml:mtext>&#x000a0;&#x000a0;</mml:mtext><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>7</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>2</mml:mn></mml:mtd><mml:mtd><mml:mtext>&#x000a0;&#x000a0;</mml:mtext><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>4</mml:mn></mml:mtd></mml:mtr></mml:mtable><mml:mtext>&#x000a0;&#x000a0;&#x000a0;</mml:mtext></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mtable><mml:mtr><mml:mtd><mml:mn>5</mml:mn><mml:mtext>&#x000a0;</mml:mtext></mml:mtd><mml:mtd><mml:mtext>&#x000a0;</mml:mtext><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>2</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>7</mml:mn><mml:mtext>&#x000a0;</mml:mtext></mml:mtd><mml:mtd><mml:mtext>&#x000a0;&#x000a0;</mml:mtext><mml:mn>4</mml:mn></mml:mtd></mml:mtr></mml:mtable></mml:mtd><mml:mtd><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext><mml:mtable><mml:mtr><mml:mtd><mml:mn>1</mml:mn><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext></mml:mtd><mml:mtd><mml:mn>1</mml:mn><mml:mo>/</mml:mo><mml:mn>5</mml:mn></mml:mtd></mml:mtr><mml:mtr><mml:mtd><mml:mn>5</mml:mn><mml:mtext>&#x000a0;&#x000a0;&#x000a0;&#x000a0;&#x000a0;</mml:mtext></mml:mtd><mml:mtd><mml:mn>1</mml:mn></mml:mtd></mml:mtr></mml:mtable><mml:mtext>&#x000a0;&#x000a0;&#x000a0;</mml:mtext></mml:mtd></mml:mtr></mml:mtable><mml:mo>]</mml:mo></mml:mrow></mml:math></alternatives>
</disp-formula><p>Based on <ext-link xlink:href="https://clincalc.com/Vancomycin/" ext-link-type="uri">https://clincalc.com/Vancomycin/</ext-link> and JPKD software, and the weight analysis of three dosing regimens (increasing dose, delaying infusion time and increasing the dosing interval) on APTT, OI, CHF and moderate/severe CKD factors. The judgment matrix of the scheme layer is shown in <xref rid="pone.0324510.t003" ref-type="table">Table 3</xref>.</p><table-wrap position="float" id="pone.0324510.t003"><object-id pub-id-type="doi">10.1371/journal.pone.0324510.t003</object-id><label>Table 3</label><caption><title>Scheme layer judgment matrix.</title></caption><alternatives><graphic xlink:href="pone.0324510.t003" id="pone.0324510.t003g" position="float"/><table frame="hsides" rules="groups"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="left" rowspan="1" colspan="1">B1</th><th align="left" rowspan="1" colspan="1">C1</th><th align="left" rowspan="1" colspan="1">C2</th><th align="left" rowspan="1" colspan="1">C3</th><th align="left" rowspan="1" colspan="1">B2</th><th align="left" rowspan="1" colspan="1">C1</th><th align="left" rowspan="1" colspan="1">C2</th><th align="left" rowspan="1" colspan="1">C3</th><th align="left" rowspan="1" colspan="1">B3</th><th align="left" rowspan="1" colspan="1">C1</th><th align="left" rowspan="1" colspan="1">C2</th><th align="left" rowspan="1" colspan="1">C3</th><th align="left" rowspan="1" colspan="1">B4</th><th align="left" rowspan="1" colspan="1">C1</th><th align="left" rowspan="1" colspan="1">C2</th><th align="left" rowspan="1" colspan="1">C3</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">C1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">C1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">C1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">C1</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">7</td></tr><tr><td align="left" rowspan="1" colspan="1">C2</td><td align="left" rowspan="1" colspan="1">1/7</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1/2</td><td align="left" rowspan="1" colspan="1">C2</td><td align="left" rowspan="1" colspan="1">1/7</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1/2</td><td align="left" rowspan="1" colspan="1">C2</td><td align="left" rowspan="1" colspan="1">1/7</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1/2</td><td align="left" rowspan="1" colspan="1">C2</td><td align="left" rowspan="1" colspan="1">1/7</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">1/2</td></tr><tr><td align="left" rowspan="1" colspan="1">C3</td><td align="left" rowspan="1" colspan="1">1/7</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">C3</td><td align="left" rowspan="1" colspan="1">1/7</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">C3</td><td align="left" rowspan="1" colspan="1">1/7</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td><td align="left" rowspan="1" colspan="1">C3</td><td align="left" rowspan="1" colspan="1">1/7</td><td align="left" rowspan="1" colspan="1">2</td><td align="left" rowspan="1" colspan="1">1</td></tr></tbody></table></alternatives></table-wrap><p>The weights of APTT, OI, CHF and moderate/severe CKD to the overexposure of <inline-formula id="pone.0324510.e030"><alternatives><graphic xlink:href="pone.0324510.e030.jpg" id="pone.0324510.e030g" position="anchor"/><mml:math id="M30" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> were 0.0584, 0.1899, 0.1614 and 0.5902, respectively. The <italic toggle="yes">CI</italic> and <italic toggle="yes">CR</italic> were 0.0796 and 0.0885, which meet the consistency test standard. It shows that the hierarchical total ranking results achieve satisfactory consistency and the analysis results were accepted. The ranking of the influencing factors was as follows: Moderate/severe CKD&#x02009;&#x0003e;&#x02009;OI&#x02009;&#x0003e;&#x02009;CHF&#x02009;&#x0003e;&#x02009;APTT. According to the definition of combination weight vector, the combination weight vector <italic toggle="yes">w</italic> = (0.7671 0.09 0.1429) was obtained by substituting the data, meaning that the contribution weights of increasing dose, increasing the dosing interval and delaying infusion time to the overexposure of <inline-formula id="pone.0324510.e031"><alternatives><graphic xlink:href="pone.0324510.e031.jpg" id="pone.0324510.e031g" position="anchor"/><mml:math id="M31" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> were 0.7671, 0.09 and 0.1429, respectively. The combination <italic toggle="yes">CI</italic> and <italic toggle="yes">CR</italic> were 0.0272 and 0.0469, separately, which meet the consistency test standard. Based on these results, the hierarchical total ranking results have satisfactory consistency and the analysis results are accepted. The effects of different dosing regimens on the vancomycin overexposure were ranked as follows: increasing dose&#x02009;&#x0003e;&#x02009;delaying infusion time&#x02009;&#x0003e;&#x02009;increasing the dosing interval.</p></sec></sec><sec sec-type="conclusions" id="sec011"><title>Discussion</title><p>The present study enrolled 194 critically ill patients with sepsis or septic shock according to the definition by the third international consensus [<xref rid="pone.0324510.ref024" ref-type="bibr">24</xref>], and international guidelines for management of sepsis and septic shock [<xref rid="pone.0324510.ref025" ref-type="bibr">25</xref>]. Tobias Zimmermann et al conducted a retrospective study of gender differences in sequential organ failure assessment (SOFA) scores in patients with sepsis or septic shock in the intensive care unit, which revealed the existence of sex-specific differences in the SOFA score of patients admitted due to sepsis or septic shock [<xref rid="pone.0324510.ref026" ref-type="bibr">26</xref>]. In addition, Emma Larsson mentioned that animal models showed that females were less susceptible to sepsis and tended to recover more effectively than males [<xref rid="pone.0324510.ref027" ref-type="bibr">27</xref>]. The different responses of female and male hosts to pathogens can be partially attributed to the sex-specific polarization of intracellular pathways that respond to pathogen-cell receptor interactions. Therefore, it may be used to explain the baseline phenomenon of gender ratio in our study.</p><p>OI is also mentioned as PaO2/FiO2, which is commonly used to measure the severity of hypoxemia in patients with respiratory failure. The importance of oxygen shows that the cells need oxygen to maintain survival and function, and hypoxia leads to irreversible damage to important organs. Whether it is ventilation dysfunction or ventilation dysfunction, oxygen can&#x02019;t be transported normally in the body, resulting in hypoxia. Through the oxygen delivery (DO2) formula [DO2&#x02009;=&#x02009;arterial oxygen content(CaO2)&#x000d7;cardiac output(CO)&#x000d7;10, CaO2&#x02009;=&#x02009;hemoglobin (Hb)&#x000d7;1.34&#x02009;&#x000d7;&#x02009;arterial oxygen saturation (SaO2)+partial pressure of arterial oxygen (PaO2)&#x000d7;0.0076}, it can be seen that the ventilation and ventilation function of the lung and the cardiac output of the heart are involved in the occurrence of hypoxemia during oxygen delivery [<xref rid="pone.0324510.ref028" ref-type="bibr">28</xref>]. Therefore, one possible explanation for <inline-formula id="pone.0324510.e032"><alternatives><graphic xlink:href="pone.0324510.e032.jpg" id="pone.0324510.e032g" position="anchor"/><mml:math id="M32" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure is the hypoxia-induced impairment of drug metabolism in patients with low OI, causing damage to the corresponding muscle cells. For another, H Wang et al showed that OI was an independent risk factor for intra-abdominal hypertension [<xref rid="pone.0324510.ref029" ref-type="bibr">29</xref>]. Additionally, it has been mentioned that intra-abdominal hypertension is not uncommon in critically ill patients, and its incidence can reach 30%&#x02009;~&#x02009;40% [<xref rid="pone.0324510.ref030" ref-type="bibr">30</xref>]. The increased intra-abdominal pressure can affect systemic hemodynamics[<xref rid="pone.0324510.ref010" ref-type="bibr">10</xref>], which may affect renal blood flow and result in the increased vancomycin concentration. In this study, OI as one of the risk factors for the excessive exposure of <inline-formula id="pone.0324510.e033"><alternatives><graphic xlink:href="pone.0324510.e033.jpg" id="pone.0324510.e033g" position="anchor"/><mml:math id="M33" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> may be due to the increase in intra-abdominal pressure caused by hypoxia index, which affects the changes of renal blood flow.</p><p>CKD is defined as renal structural or functional abnormalities for more than 3 months [<xref rid="pone.0324510.ref031" ref-type="bibr">31</xref>]. For CKD patients, not only the renal clearance rate decreases, but also the liver drug enzyme activity decreases from 5% to 50% [<xref rid="pone.0324510.ref032" ref-type="bibr">32</xref>]. In our study, there was statistically significant difference in the compliant group (5.26%) compared with the overexposure group (27.73%) in patients with moderate/severe CKD (<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.001). Through the multivariate logistic regression and AHP analyses, moderate/severe CKD was one of the risk factors leading to <inline-formula id="pone.0324510.e034"><alternatives><graphic xlink:href="pone.0324510.e034.jpg" id="pone.0324510.e034g" position="anchor"/><mml:math id="M34" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure. In addition, it is reported that the risk of infection in CKD patients is 3&#x02009;~&#x02009;4 times higher than that in normal people [<xref rid="pone.0324510.ref033" ref-type="bibr">33</xref>]. Further, <inline-formula id="pone.0324510.e035"><alternatives><graphic xlink:href="pone.0324510.e035.jpg" id="pone.0324510.e035g" position="anchor"/><mml:math id="M35" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> values over 21.5&#x02009;mg/L and 16.5&#x02009;mg/L are associated with an increased risk of vancomycin-induced nephrotoxicity in CKD Stage 3a and 3b-5 [<xref rid="pone.0324510.ref034" ref-type="bibr">34</xref>], respectively. Similar to these studies, our results suggested that kidney disease might affect <inline-formula id="pone.0324510.e036"><alternatives><graphic xlink:href="pone.0324510.e036.jpg" id="pone.0324510.e036g" position="anchor"/><mml:math id="M36" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure.</p><p>CHF is generally defined as the inability of the heart to supply sufficient blood flow to meet the needs of the body [<xref rid="pone.0324510.ref035" ref-type="bibr">35</xref>]. Due to the decreased cardiac output and the decreased renal blood flow, CHF can alter the pharmacokinetics of various drugs. In our study, through multivariate logistic regression analysis of factors affecting <inline-formula id="pone.0324510.e037"><alternatives><graphic xlink:href="pone.0324510.e037.jpg" id="pone.0324510.e037g" position="anchor"/><mml:math id="M37" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure, the results showed that the OR and 95%CI for CHF factor were 5.023 and 1.033&#x02009;~&#x02009;24.430 (<italic toggle="yes">P</italic>&#x02009;=&#x02009;0.046). This indicates that CHF may be another risk factor leading to <inline-formula id="pone.0324510.e038"><alternatives><graphic xlink:href="pone.0324510.e038.jpg" id="pone.0324510.e038g" position="anchor"/><mml:math id="M38" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure, which can be explained by the relevant literature. Shammas et al showed the major influences of CHF on drug pharmacokinetics, which were duction in the volume of distribution and an impairment of elimination clearance, and consequently a prolonged elimination half-life [<xref rid="pone.0324510.ref035" ref-type="bibr">35</xref>]. Yuko Shimamoto et al summarized that vancomycin clearance, which was affected by cardiac function, decreased with the decreasing cardiac function and the decreasing creatinine clearance [<xref rid="pone.0324510.ref036" ref-type="bibr">36</xref>].</p><p>APTT is a screening test for endogenous coagulation factors. The prolongation of APTT is common in coagulation factor deficiency, and its shortening indicates that the blood is in a hypercoagulable state. The laboratory examination of DIC includes PT, APTT, fibrinogen concentration and platelet count that reflect the consumption of coagulation factors [<xref rid="pone.0324510.ref037" ref-type="bibr">37</xref>]. Clinically, the incidence of DIC is relatively high in critically ill patients. DIC symptoms occur in 10%&#x02009;~&#x02009;30% of critically ill patients, which complicates the clinical course and increases the mortality of patients [<xref rid="pone.0324510.ref038" ref-type="bibr">38</xref>]. Besides, infection is the most important cause of DIC, and 30%&#x02009;~&#x02009;51% of infected patients may develop the DIC symptoms [<xref rid="pone.0324510.ref039" ref-type="bibr">39</xref>]. Our study included 194 critically ill patients. There were statistical differences in PCT, PT, APTT and INR between the compliant and overexposure groups (<italic toggle="yes">P</italic>&#x02009;&#x0003c;&#x02009;0.05). DIC can cause the body coagulation-anticoagulation-fibrinolysis system disorders, massive microvascular thrombosis, and ultimately induce bleeding, multiple organ failure and other symptoms, which may alter the vancomycin pharmacokinetics. Therefore, the reason for the increase of <inline-formula id="pone.0324510.e039"><alternatives><graphic xlink:href="pone.0324510.e039.jpg" id="pone.0324510.e039g" position="anchor"/><mml:math id="M39" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> in critically ill patients with DIC may be related to the multi-organ failure caused by DIC. Through the multiple logistic regression and AHP, APTT may be another risk factor leading to <inline-formula id="pone.0324510.e040"><alternatives><graphic xlink:href="pone.0324510.e040.jpg" id="pone.0324510.e040g" position="anchor"/><mml:math id="M40" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure.</p><p>In the present study, with the reason of <inline-formula id="pone.0324510.e041"><alternatives><graphic xlink:href="pone.0324510.e041.jpg" id="pone.0324510.e041g" position="anchor"/><mml:math id="M41" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure being the target layer, and the factors after multiple logistic regression being the criterion layer, the AHP model was constructed (<xref rid="pone.0324510.g003" ref-type="fig">Fig 3</xref>). The hierarchical total ranking results had satisfactory consistency and thus were accepted (<italic toggle="yes">CR&#x02009;</italic>=&#x02009;0.0469&#x02009;&#x0003c;&#x02009;0.1). The ranking of the influencing factors was as follows: Moderate/severe CKD&#x02009;&#x0003e;&#x02009;OI&#x02009;&#x0003e;&#x02009;CHF&#x02009;&#x0003e;&#x02009;APTT. And the scheme layer sorting was ranked as follows: increasing dose&#x02009;&#x0003e;&#x02009;delaying infusion time&#x02009;&#x0003e;&#x02009;increasing the dosing interval. Therefore, if excessive <inline-formula id="pone.0324510.e042"><alternatives><graphic xlink:href="pone.0324510.e042.jpg" id="pone.0324510.e042g" position="anchor"/><mml:math id="M42" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> was exposed, the vancomycin dosing regimen could be adopted as follows: reducing the dosage&#x02009;&#x0003e;&#x02009;shortening the infusion time (more than 60&#x02009;min of infusion according to the drug instructions)&#x0003e; reducing the dosing interval.</p><fig position="float" id="pone.0324510.g003"><object-id pub-id-type="doi">10.1371/journal.pone.0324510.g003</object-id><label>Fig 3</label><caption><title>Flow chart of the AHP.</title></caption><graphic xlink:href="pone.0324510.g003" position="float"/></fig></sec><sec sec-type="conclusions" id="sec012"><title>Conclusions</title><p>Our investigation systematically reveals the clinical prioritization of factors influencing <inline-formula id="pone.0324510.e043"><alternatives><graphic xlink:href="pone.0324510.e043.jpg" id="pone.0324510.e043g" position="anchor"/><mml:math id="M43" display="inline" overflow="scroll"><mml:mrow><mml:msub><mml:mi>C</mml:mi><mml:mrow><mml:mi>v</mml:mi><mml:mi>g</mml:mi><mml:mo>&#x02212;</mml:mo><mml:mi>m</mml:mi><mml:mi>i</mml:mi><mml:mi>n</mml:mi></mml:mrow></mml:msub></mml:mrow></mml:math></alternatives></inline-formula> overexposure in mechanically ventilated critically ill patients. The derived clinically significant ranking demonstrates that moderate/severe CKD is the predominant determinant, followed by OI impairment, CHF and APTT alterations. This evidence-based hierarchy provides crucial insights for clinical decision-making regarding the risk stratification and intervention prioritization in the critical care settings. However, these findings should be interpreted with caution due to the limitations of this study, including its single-center design and relatively small sample size. Future multi-center studies with larger cohorts are warranted.</p></sec></body><back><ack><p>We thank all the medical staff who participated in the implementation of this study, data collection and processing, article writing, clinical guidance and so on.</p></ack><ref-list><title>References</title><ref id="pone.0324510.ref001"><label>1</label><mixed-citation publication-type="journal"><name><surname>Akunne</surname><given-names>OO</given-names></name>, <name><surname>Mugabo</surname><given-names>P</given-names></name>, <name><surname>Argent</surname><given-names>AC</given-names></name>. <article-title>Pharmacokinetics of Vancomycin in Critically Ill Children: A Systematic Review</article-title>. <source>Eur J Drug Metab Pharmacokinet</source>. <year>2022</year>;<volume>47</volume>(<issue>1</issue>):<fpage>31</fpage>&#x02013;<lpage>48</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s13318-021-00730-z</pub-id>
<pub-id pub-id-type="pmid">34750740</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref002"><label>2</label><mixed-citation publication-type="journal"><name><surname>Geraci</surname><given-names>JE</given-names></name>, <name><surname>Heilman</surname><given-names>FR</given-names></name>, <name><surname>Nichols</surname><given-names>DR</given-names></name>, <name><surname>Wellman</surname><given-names>EW</given-names></name>, <name><surname>Ross</surname><given-names>GT</given-names></name>. <article-title>Some laboratory and clinical experiences with a new antibiotic, vancomycin</article-title>. <source>Antibiotics Annu</source>. <volume>1956</volume>:<fpage>90</fpage>&#x02013;<lpage>106</lpage>.</mixed-citation></ref><ref id="pone.0324510.ref003"><label>3</label><mixed-citation publication-type="journal"><name><surname>Levine</surname><given-names>DP</given-names></name>. <article-title>Vancomycin: a history</article-title>. <source>Clin Infect Dis</source>. <year>2006</year>;42 Suppl 1:S5-12. <comment>doi: </comment><pub-id pub-id-type="doi">10.1086/491709</pub-id>
<pub-id pub-id-type="pmid">16323120</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref004"><label>4</label><mixed-citation publication-type="journal"><name><surname>Bruniera</surname><given-names>FR</given-names></name>, <name><surname>Ferreira</surname><given-names>FM</given-names></name>, <name><surname>Saviolli</surname><given-names>LRM</given-names></name>, <name><surname>Bacci</surname><given-names>MR</given-names></name>, <name><surname>Feder</surname><given-names>D</given-names></name>, <name><surname>da Luz Gon&#x000e7;alves Pedreira</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>The use of vancomycin with its therapeutic and adverse effects: a review</article-title>. <source>Eur Rev Med Pharmacol Sci</source>. <year>2015</year>;<volume>19</volume>(<issue>4</issue>):<fpage>694</fpage>&#x02013;<lpage>700</lpage>. <pub-id pub-id-type="pmid">25753888</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref005"><label>5</label><mixed-citation publication-type="journal"><name><surname>Mali</surname><given-names>NB</given-names></name>, <name><surname>Tullu</surname><given-names>MS</given-names></name>, <name><surname>Wandalkar</surname><given-names>PP</given-names></name>, <name><surname>Deshpande</surname><given-names>SP</given-names></name>, <name><surname>Ingale</surname><given-names>VC</given-names></name>, <name><surname>Deshmukh</surname><given-names>CT</given-names></name>, <etal>et al</etal>. <article-title>Steady-state Pharmacokinetics of Vancomycin in Children Admitted to Pediatric Intensive Care Unit of a Tertiary Referral Center</article-title>. <source>Indian J Crit Care Med</source>. <year>2019</year>;<volume>23</volume>(<issue>11</issue>):<fpage>497</fpage>&#x02013;<lpage>502</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5005/jp-journals-10071-23275</pub-id>
<pub-id pub-id-type="pmid">31911739</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref006"><label>6</label><mixed-citation publication-type="journal"><name><surname>Bonazza</surname><given-names>S</given-names></name>, <name><surname>Bresee</surname><given-names>LC</given-names></name>, <name><surname>Kraft</surname><given-names>T</given-names></name>, <name><surname>Ross</surname><given-names>BC</given-names></name>, <name><surname>Dersch-Mills</surname><given-names>D</given-names></name>. <article-title>Frequency of and Risk Factors for Acute Kidney Injury Associated With Vancomycin Use in the Pediatric Intensive Care Unit</article-title>. <source>J Pediatr Pharmacol Ther</source>. <year>2016</year>;<volume>21</volume>(<issue>6</issue>):<fpage>486</fpage>&#x02013;<lpage>93</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5863/1551-6776-21.6.486</pub-id>
<pub-id pub-id-type="pmid">28018150</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref007"><label>7</label><mixed-citation publication-type="journal"><name><surname>Sakai</surname><given-names>Y</given-names></name>, <name><surname>Miwa</surname><given-names>R</given-names></name>, <name><surname>Mitsuoka</surname><given-names>M</given-names></name>, <name><surname>Watanabe</surname><given-names>H</given-names></name>. <article-title>Combinatorial vancomycin and piperacillin/tazobactam results in elevated vancomycin trough concentration and acute kidney injury: a case report</article-title>. <source>Yakugaku Zasshi</source>. <year>2020</year>;<volume>140</volume>:<fpage>751</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">32378679</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref008"><label>8</label><mixed-citation publication-type="journal"><name><surname>Sawada</surname><given-names>A</given-names></name>, <name><surname>Kawanishi</surname><given-names>K</given-names></name>, <name><surname>Morikawa</surname><given-names>S</given-names></name>, <name><surname>Nakano</surname><given-names>T</given-names></name>, <name><surname>Kodama</surname><given-names>M</given-names></name>, <name><surname>Mitobe</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Biopsy-proven vancomycin-induced acute kidney injury: a case report and literature review</article-title>. <source>BMC Nephrol</source>. <year>2018</year>;<volume>19</volume>(<issue>1</issue>):<fpage>72</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s12882-018-0845-1</pub-id>
<pub-id pub-id-type="pmid">29587650</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref009"><label>9</label><mixed-citation publication-type="journal"><name><surname>Nooreddeen</surname><given-names>EA</given-names></name>, <name><surname>Alzahrani</surname><given-names>RM</given-names></name>, <name><surname>Alshanqiti</surname><given-names>NM</given-names></name>. <article-title>Severe Vancomycin Intoxication in an Infant Not Needing Dialysis: A Case Report and Literature Review</article-title>. <source>Cureus</source>. <year>2022</year>; <volume>14</volume>: e31950.</mixed-citation></ref><ref id="pone.0324510.ref010"><label>10</label><mixed-citation publication-type="journal"><name><surname>Ye</surname><given-names>Z-K</given-names></name>, <name><surname>Chen</surname><given-names>Y-L</given-names></name>, <name><surname>Chen</surname><given-names>K</given-names></name>, <name><surname>Zhang</surname><given-names>X-L</given-names></name>, <name><surname>Du</surname><given-names>G-H</given-names></name>, <name><surname>He</surname><given-names>B</given-names></name>, <etal>et al</etal>. <article-title>Therapeutic drug monitoring of vancomycin: a guideline of the Division of Therapeutic Drug Monitoring, Chinese Pharmacological Society</article-title>. <source>J Antimicrob Chemother</source>. <year>2016</year>;<volume>71</volume>(<issue>11</issue>):<fpage>3020</fpage>&#x02013;<lpage>5</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/jac/dkw254</pub-id>
<pub-id pub-id-type="pmid">27494905</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref011"><label>11</label><mixed-citation publication-type="journal"><name><surname>Liu</surname><given-names>C</given-names></name>, <name><surname>Bayer</surname><given-names>A</given-names></name>, <name><surname>Cosgrove</surname><given-names>SE</given-names></name>, <name><surname>Daum</surname><given-names>RS</given-names></name>, <name><surname>Fridkin</surname><given-names>SK</given-names></name>, <name><surname>Gorwitz</surname><given-names>RJ</given-names></name>, <etal>et al</etal>. <article-title>Clinical practice guidelines by the infectious diseases society of america for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children</article-title>. <source>Clin Infect Dis</source>. <year>2011</year>;<volume>52</volume>(<issue>3</issue>):e18-55. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/cid/ciq146</pub-id>
<pub-id pub-id-type="pmid">21208910</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref012"><label>12</label><mixed-citation publication-type="journal"><name><surname>Drennan</surname><given-names>PG</given-names></name>, <name><surname>Begg</surname><given-names>EJ</given-names></name>, <name><surname>Gardiner</surname><given-names>SJ</given-names></name>, <name><surname>Kirkpatrick</surname><given-names>CMJ</given-names></name>, <name><surname>Chambers</surname><given-names>ST</given-names></name>. <article-title>The dosing and monitoring of vancomycin: what is the best way forward?</article-title>. <source>Int J Antimicrob Agents</source>. <year>2019</year>;<volume>53</volume>(<issue>4</issue>):<fpage>401</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1016/j.ijantimicag.2018.12.014</pub-id>
<pub-id pub-id-type="pmid">30599240</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref013"><label>13</label><mixed-citation publication-type="journal"><name><surname>Elyasi</surname><given-names>S</given-names></name>, <name><surname>Khalili</surname><given-names>H</given-names></name>, <name><surname>Dashti-Khavidaki</surname><given-names>S</given-names></name>, <name><surname>Mohammadpour</surname><given-names>A</given-names></name>. <article-title>Vancomycin-induced nephrotoxicity: mechanism, incidence, risk factors and special populations. A literature review</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2012</year>;<volume>68</volume>(<issue>9</issue>):<fpage>1243</fpage>&#x02013;<lpage>55</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00228-012-1259-9</pub-id>
<pub-id pub-id-type="pmid">22411630</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref014"><label>14</label><mixed-citation publication-type="journal"><name><surname>Kishk</surname><given-names>OA</given-names></name>, <name><surname>Lardieri</surname><given-names>AB</given-names></name>, <name><surname>Heil</surname><given-names>EL</given-names></name>, <name><surname>Morgan</surname><given-names>JA</given-names></name>. <article-title>Vancomycin AUC/MIC and Corresponding Troughs in a Pediatric Population</article-title>. <source>J Pediatr Pharmacol Ther</source>. <year>2017</year>;<volume>22</volume>(<issue>1</issue>):<fpage>41</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5863/1551-6776-22.1.41</pub-id>
<pub-id pub-id-type="pmid">28337080</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref015"><label>15</label><mixed-citation publication-type="journal"><name><surname>&#x000c1;lvarez-Lerma</surname><given-names>F</given-names></name>, <name><surname>Grau</surname><given-names>S</given-names></name>. <article-title>Management of antimicrobial use in the intensive care unit</article-title>. <source>Drugs</source>. <year>2012</year>;<volume>72</volume>(<issue>4</issue>):<fpage>447</fpage>&#x02013;<lpage>70</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2165/11599520-000000000-00000</pub-id>
<pub-id pub-id-type="pmid">22303918</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref016"><label>16</label><mixed-citation publication-type="journal"><name><surname>Rybak</surname><given-names>MJ</given-names></name>, <name><surname>Lomaestro</surname><given-names>BM</given-names></name>, <name><surname>Rotschafer</surname><given-names>JC</given-names></name>, <name><surname>Moellering</surname><given-names>RC</given-names></name>, <name><surname>Craig</surname><given-names>WA</given-names></name>, <name><surname>Billeter</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Vancomycin therapeutic guidelines: a summary of consensus recommendations from the infectious diseases Society of America, the American Society of Health-System Pharmacists, and the Society of Infectious Diseases Pharmacists</article-title>. <source>Clin Infect Dis</source>. <year>2009</year>;<volume>49</volume>(<issue>3</issue>):<fpage>325</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1086/600877</pub-id>
<pub-id pub-id-type="pmid">19569969</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref017"><label>17</label><mixed-citation publication-type="journal"><name><surname>Campassi</surname><given-names>ML</given-names></name>, <name><surname>Gonzalez</surname><given-names>MC</given-names></name>, <name><surname>Masevicius</surname><given-names>FD</given-names></name>, <name><surname>Vazquez</surname><given-names>AR</given-names></name>, <name><surname>Moseinco</surname><given-names>M</given-names></name>, <name><surname>Navarro</surname><given-names>NC</given-names></name>, <etal>et al</etal>. <article-title>Augmented renal clearance in critically ill patients: incidence, associated factors and effects on vancomycin treatment</article-title>. <source>Rev Bras Ter Intensiva</source>. <year>2014</year>;<volume>26</volume>(<issue>1</issue>):<fpage>13</fpage>&#x02013;<lpage>20</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5935/0103-507x.20140003</pub-id>
<pub-id pub-id-type="pmid">24770684</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref018"><label>18</label><mixed-citation publication-type="journal"><name><surname>Medell&#x000ed;n-Garibay</surname><given-names>SE</given-names></name>, <name><surname>Ortiz-Mart&#x000ed;n</surname><given-names>B</given-names></name>, <name><surname>Rueda-Naharro</surname><given-names>A</given-names></name>, <name><surname>Garc&#x000ed;a</surname><given-names>B</given-names></name>, <name><surname>Romano-Moreno</surname><given-names>S</given-names></name>, <name><surname>Barcia</surname><given-names>E</given-names></name>. <article-title>Pharmacokinetics of vancomycin and dosing recommendations for trauma patients</article-title>. <source>J Antimicrob Chemother</source>. <year>2016</year>;<volume>71</volume>(<issue>2</issue>):<fpage>471</fpage>&#x02013;<lpage>9</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/jac/dkv372</pub-id>
<pub-id pub-id-type="pmid">26568565</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref019"><label>19</label><mixed-citation publication-type="journal"><name><surname>Minkut&#x00117;</surname><given-names>R</given-names></name>, <name><surname>Briedis</surname><given-names>V</given-names></name>, <name><surname>Steponavi&#x0010d;i&#x0016b;t&#x00117;</surname><given-names>R</given-names></name>, <name><surname>Vitkauskien&#x00117;</surname><given-names>A</given-names></name>, <name><surname>Ma&#x0010d;iulaitis</surname><given-names>R</given-names></name>. <article-title>Augmented renal clearance--an evolving risk factor to consider during the treatment with vancomycin</article-title>. <source>J Clin Pharm Ther</source>. <year>2013</year>;<volume>38</volume>(<issue>6</issue>):<fpage>462</fpage>&#x02013;<lpage>7</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/jcpt.12088</pub-id>
<pub-id pub-id-type="pmid">23924288</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref020"><label>20</label><mixed-citation publication-type="journal"><name><surname>Rosini</surname><given-names>JM</given-names></name>, <name><surname>Laughner</surname><given-names>J</given-names></name>, <name><surname>Levine</surname><given-names>BJ</given-names></name>, <name><surname>Papas</surname><given-names>MA</given-names></name>, <name><surname>Reinhardt</surname><given-names>JF</given-names></name>, <name><surname>Jasani</surname><given-names>NB</given-names></name>. <article-title>A randomized trial of loading vancomycin in the emergency department</article-title>. <source>Ann Pharmacother</source>. <year>2015</year>;<volume>49</volume>(<issue>1</issue>):<fpage>6</fpage>&#x02013;<lpage>13</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1177/1060028014556813</pub-id>
<pub-id pub-id-type="pmid">25358330</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref021"><label>21</label><mixed-citation publication-type="journal"><name><surname>Wilson</surname><given-names>FP</given-names></name>, <name><surname>Berns</surname><given-names>JS</given-names></name>. <article-title>Vancomycin levels are frequently subtherapeutic during continuous venovenous hemodialysis (CVVHD)</article-title>. <source>Clin Nephrol</source>. <year>2012</year>;<volume>77</volume>(<issue>4</issue>):<fpage>329</fpage>&#x02013;<lpage>31</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.5414/cn106993</pub-id>
<pub-id pub-id-type="pmid">22445477</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref022"><label>22</label><mixed-citation publication-type="journal"><name><surname>Bakke</surname><given-names>V</given-names></name>, <name><surname>Sporsem</surname><given-names>H</given-names></name>, <name><surname>Von der Lippe</surname><given-names>E</given-names></name>, <name><surname>Nord&#x000f8;y</surname><given-names>I</given-names></name>, <name><surname>Lao</surname><given-names>Y</given-names></name>, <name><surname>Nyrer&#x000f8;d</surname><given-names>HC</given-names></name>, <etal>et al</etal>. <article-title>Vancomycin levels are frequently subtherapeutic in critically ill patients: a prospective observational study</article-title>. <source>Acta Anaesthesiol Scand</source>. <year>2017</year>;<volume>61</volume>(<issue>6</issue>):<fpage>627</fpage>&#x02013;<lpage>35</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/aas.12897</pub-id>
<pub-id pub-id-type="pmid">28444760</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref023"><label>23</label><mixed-citation publication-type="journal"><name><surname>Jiong</surname><given-names>T</given-names></name>, <name><surname>Ying</surname><given-names>L</given-names></name>. <article-title>Literature analysis of adverse drug reactions induced by three types of anti-MRSA drugs</article-title>. <source>World notes on antibiotics</source>. <year>2021</year>;<volume>42</volume>:<fpage>82</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="pone.0324510.ref024"><label>24</label><mixed-citation publication-type="journal"><name><surname>Singer</surname><given-names>M</given-names></name>, <name><surname>Deutschman</surname><given-names>CS</given-names></name>, <name><surname>Seymour</surname><given-names>CW</given-names></name>, <name><surname>Shankar-Hari</surname><given-names>M</given-names></name>, <name><surname>Annane</surname><given-names>D</given-names></name>, <name><surname>Bauer</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)</article-title>. <source>JAMA</source>. <year>2016</year>;<volume>315</volume>(<issue>8</issue>):<fpage>801</fpage>&#x02013;<lpage>10</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1001/jama.2016.0287</pub-id>
<pub-id pub-id-type="pmid">26903338</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref025"><label>25</label><mixed-citation publication-type="journal"><name><surname>Evans</surname><given-names>L</given-names></name>, <name><surname>Rhodes</surname><given-names>A</given-names></name>, <name><surname>Alhazzani</surname><given-names>W</given-names></name>, <name><surname>Antonelli</surname><given-names>M</given-names></name>, <name><surname>Coopersmith</surname><given-names>CM</given-names></name>, <name><surname>French</surname><given-names>C</given-names></name>, <etal>et al</etal>. <article-title>Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021</article-title>. <source>Intensive Care Med</source>. <year>2021</year>;<volume>47</volume>(<issue>11</issue>):<fpage>1181</fpage>&#x02013;<lpage>247</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00134-021-06506-y</pub-id>
<pub-id pub-id-type="pmid">34599691</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref026"><label>26</label><mixed-citation publication-type="journal"><name><surname>Zimmermann</surname><given-names>T</given-names></name>, <name><surname>Kaufmann</surname><given-names>P</given-names></name>, <name><surname>Amacher</surname><given-names>SA</given-names></name>, <name><surname>Sutter</surname><given-names>R</given-names></name>, <name><surname>Loosen</surname><given-names>G</given-names></name>, <name><surname>Merdji</surname><given-names>H</given-names></name>, <etal>et al</etal>. <article-title>Sex differences in the SOFA score of ICU patients with sepsis or septic shock: a nationwide analysis</article-title>. <source>Crit Care</source>. <year>2024</year>;<volume>28</volume>(<issue>1</issue>):<fpage>209</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13054-024-04996-y</pub-id>
<pub-id pub-id-type="pmid">38937819</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref027"><label>27</label><mixed-citation publication-type="journal"><name><surname>Larsson</surname><given-names>E</given-names></name>. <article-title>Sex matters: Is it time for a SOFA makeover?</article-title>. <source>Crit Care</source>. <year>2024</year>;<volume>28</volume>(<issue>1</issue>):<fpage>268</fpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1186/s13054-024-05030-x</pub-id>
<pub-id pub-id-type="pmid">39118159</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref028"><label>28</label><mixed-citation publication-type="journal"><name><surname>Boveris</surname><given-names>DL</given-names></name>, <name><surname>Boveris</surname><given-names>A</given-names></name>. <article-title>Oxygen delivery to the tissues and mitochondrial respiration</article-title>. <source>Front Biosci</source>. <year>2007</year>;<volume>12</volume>:<fpage>1014</fpage>&#x02013;<lpage>23</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2741/2121</pub-id>
<pub-id pub-id-type="pmid">17127356</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref029"><label>29</label><mixed-citation publication-type="journal"><name><surname>Wang</surname><given-names>H</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>, <name><surname>Li</surname><given-names>Y</given-names></name>, <name><surname>Chang</surname><given-names>W</given-names></name>. <article-title>The impact of relevant factors in mechanical ventilation on intra-abdominal pressure in patients with ALI/ARDS</article-title>. <source>Chin J Emerg Med</source>. <year>2015</year>;<volume>24</volume>:<fpage>1430</fpage>&#x02013;<lpage>5</lpage>.</mixed-citation></ref><ref id="pone.0324510.ref030"><label>30</label><mixed-citation publication-type="journal"><name><surname>Association</surname><given-names>C</given-names></name>. <article-title>Expert consensus on monitoring and management of intra-abdominal hypertension in severe patients</article-title>. <source>Chin J Dig Surg</source>. <year>2020</year>;<volume>19</volume>:<fpage>1030</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="pone.0324510.ref031"><label>31</label><mixed-citation publication-type="journal"><name><surname>Andrassy</surname><given-names>KM</given-names></name>. <article-title>Comments on &#x0201c;KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease&#x0201d;</article-title>. <source>Kidney Int</source>. <year>2013</year>;<volume>84</volume>(<issue>3</issue>):<fpage>622</fpage>&#x02013;<lpage>3</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1038/ki.2013.243</pub-id>
<pub-id pub-id-type="pmid">23989362</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref032"><label>32</label><mixed-citation publication-type="journal"><name><surname>Vondracek</surname><given-names>SF</given-names></name>, <name><surname>Teitelbaum</surname><given-names>I</given-names></name>, <name><surname>Kiser</surname><given-names>TH</given-names></name>. <article-title>Principles of Kidney Pharmacotherapy for the Nephrologist: Core Curriculum 2021</article-title>. <source>Am J Kidney Dis</source>. <year>2021</year>;<volume>78</volume>(<issue>3</issue>):<fpage>442</fpage>&#x02013;<lpage>58</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1053/j.ajkd.2021.02.342</pub-id>
<pub-id pub-id-type="pmid">34275659</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref033"><label>33</label><mixed-citation publication-type="journal"><collab>Expert Group on Kidney Clinical Quality Control Center in S</collab>. <article-title>Guidelines for early screening, diagnosis, prevention and treatment of chronic kidney disease (2022 edition)</article-title>. <source>Chin J Nephrol</source>. <year>2022</year>;<volume>38</volume>:<fpage>453</fpage>&#x02013;<lpage>64</lpage>.</mixed-citation></ref><ref id="pone.0324510.ref034"><label>34</label><mixed-citation publication-type="journal"><name><surname>Dai</surname><given-names>N</given-names></name>, <name><surname>Jiang</surname><given-names>C</given-names></name>, <name><surname>Wang</surname><given-names>Y</given-names></name>. <article-title>Relationship between vancomycin-induced nephrotoxicity and vancomycin trough concentration in older adults: A retrospective observational study</article-title>. <source>Indian J Pharmacol</source>. <year>2023</year>;<volume>55</volume>(<issue>3</issue>):<fpage>155</fpage>&#x02013;<lpage>61</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.4103/ijp.ijp_634_22</pub-id>
<pub-id pub-id-type="pmid">37555409</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref035"><label>35</label><mixed-citation publication-type="journal"><name><surname>Shammas</surname><given-names>FV</given-names></name>, <name><surname>Dickstein</surname><given-names>K</given-names></name>. <article-title>Clinical pharmacokinetics in heart failure. An updated review</article-title>. <source>Clin Pharmacokinet</source>. <year>1988</year>;<volume>15</volume>(<issue>2</issue>):<fpage>94</fpage>&#x02013;<lpage>113</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.2165/00003088-198815020-00002</pub-id>
<pub-id pub-id-type="pmid">3064953</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref036"><label>36</label><mixed-citation publication-type="journal"><name><surname>Shimamoto</surname><given-names>Y</given-names></name>, <name><surname>Fukuda</surname><given-names>T</given-names></name>, <name><surname>Tominari</surname><given-names>S</given-names></name>, <name><surname>Fukumoto</surname><given-names>K</given-names></name>, <name><surname>Ueno</surname><given-names>K</given-names></name>, <name><surname>Dong</surname><given-names>M</given-names></name>, <etal>et al</etal>. <article-title>Decreased vancomycin clearance in patients with congestive heart failure</article-title>. <source>Eur J Clin Pharmacol</source>. <year>2013</year>;<volume>69</volume>(<issue>3</issue>):<fpage>449</fpage>&#x02013;<lpage>57</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1007/s00228-012-1340-4</pub-id>
<pub-id pub-id-type="pmid">22791272</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref037"><label>37</label><mixed-citation publication-type="journal"><name><surname>Thrombosis and Hemostasis</surname><given-names>Group</given-names></name>, <name><surname>Hematology Society of Chinese Medical</surname><given-names>Association</given-names></name>. <article-title>Consensus of Chinese experts on diagnosis of disseminated intravascular coagulation</article-title>. <source>Chin J Hematol</source>. <year>2017</year>;<volume>38</volume>:<fpage>361</fpage>&#x02013;<lpage>3</lpage>.</mixed-citation></ref><ref id="pone.0324510.ref038"><label>38</label><mixed-citation publication-type="journal"><name><surname>Adelborg</surname><given-names>K</given-names></name>, <name><surname>Larsen</surname><given-names>JB</given-names></name>, <name><surname>Hvas</surname><given-names>A-M</given-names></name>. <article-title>Disseminated intravascular coagulation: epidemiology, biomarkers, and management</article-title>. <source>Br J Haematol</source>. <year>2021</year>;<volume>192</volume>(<issue>5</issue>):<fpage>803</fpage>&#x02013;<lpage>18</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1111/bjh.17172</pub-id>
<pub-id pub-id-type="pmid">33555051</pub-id>
</mixed-citation></ref><ref id="pone.0324510.ref039"><label>39</label><mixed-citation publication-type="journal"><name><surname>Boral</surname><given-names>BM</given-names></name>, <name><surname>Williams</surname><given-names>DJ</given-names></name>, <name><surname>Boral</surname><given-names>LI</given-names></name>. <article-title>Disseminated Intravascular Coagulation</article-title>. <source>Am J Clin Pathol</source>. <year>2016</year>;<volume>146</volume>(<issue>6</issue>):<fpage>670</fpage>&#x02013;<lpage>80</lpage>. <comment>doi: </comment><pub-id pub-id-type="doi">10.1093/ajcp/aqw195</pub-id>
<pub-id pub-id-type="pmid">28013226</pub-id>
</mixed-citation></ref></ref-list></back></article>